Ripamonti, Carla I <br/><br/>
Prevention and management of osteonecrosis of the jaw secondary to bone-targeted therapy in patients with kidney cancer.  [electronic resource] 

 -  Current opinion in supportive and palliative care  09 2016 
 - 273-80 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1751-4266 
<br/><br/><label>Standard No.: </label>10.1097/SPC.0000000000000219  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Bisphosphonate-Associated Osteonecrosis of the Jaw--prevention & control<br/>Bone Density Conservation Agents--administration & dosage<br/>Bone Neoplasms--prevention & control<br/>Clinical Trials as Topic<br/>Denosumab--administration & dosage<br/>Diphosphonates--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Imidazoles--administration & dosage<br/>Kidney Neoplasms--pathology<br/>Male<br/>Quality of Life<br/>Sex Factors<br/>Zoledronic Acid